140 related articles for article (PubMed ID: 23735152)
1. Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient.
Yamada S; Tsuruya K; Kitazono T
Ther Apher Dial; 2013 Jun; 17(3):348-9. PubMed ID: 23735152
[No Abstract] [Full Text] [Related]
2. Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet.
Yokoyama K; Ohkido I; Iwamoto T; Ishida M; Urashima M; Hosoya T
Clin Nephrol; 2012 Jul; 78(1):85-6. PubMed ID: 22732343
[No Abstract] [Full Text] [Related]
3. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
Iseki K
Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?
Vervloet MG; du Buf-Vereijken PW; Potter van Loon BJ; Manamley N; Reichert LJ; Smak Gregoor PJ
Neth J Med; 2013 Sep; 71(7):348-54. PubMed ID: 24038560
[TBL] [Abstract][Full Text] [Related]
5. [Treatment with cinacalcet in secondary hyperparathyroidism for dialysis patients: The will is good--but what about the evidence?].
Bárány P; Elinder CG; Samuelsson O
Lakartidningen; 2013 Aug 21-Sep 3; 110(34-35):1481-3. PubMed ID: 24044187
[No Abstract] [Full Text] [Related]
6. Change in coronary artery calcification score due to cinacalcet hydrochloride administration.
Tsuruta Y; Ohbayashi T; Fujii M; Myochin H; Mizutani R; Narita M; Maeda K
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S34-7. PubMed ID: 19032525
[TBL] [Abstract][Full Text] [Related]
7. [Calcimimetic drugs in stage 3-5 chronic kidney disease].
Grzegorzewska AE; Niepolski L
Pol Merkur Lekarski; 2012 Apr; 32(190):260-2. PubMed ID: 22708286
[TBL] [Abstract][Full Text] [Related]
8. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
[TBL] [Abstract][Full Text] [Related]
9. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
[TBL] [Abstract][Full Text] [Related]
10. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.
Komaba H; Koizumi M; Tanaka H; Takahashi H; Sawada K; Kakuta T; Fukagawa M
Nephrol Dial Transplant; 2012 May; 27(5):1967-9. PubMed ID: 22140124
[TBL] [Abstract][Full Text] [Related]
11. What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
Moe SM; Thadhani R
Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):651-5. PubMed ID: 24100218
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.
Portolés J; López-Sánchez P; Bajo MA; Castellano I; del Peso G; Rodríguez JR; Ribera M; Ortigosa A; Selgas R
Perit Dial Int; 2012; 32(2):208-11. PubMed ID: 22383721
[No Abstract] [Full Text] [Related]
13. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
Drüeke TB
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
[TBL] [Abstract][Full Text] [Related]
14. Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism.
Bahner U; Brandl M; Nies C; Schmidt-Gayk H
J Ren Nutr; 2008 Jul; 18(4):383-8. PubMed ID: 18558304
[TBL] [Abstract][Full Text] [Related]
15. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
[TBL] [Abstract][Full Text] [Related]
16. Regression of vascular calcification in a patient treated with cinacalcet: a case report.
Salgueira M; Martínez AI; Milán JA
Nefrologia; 2011; 31(5):602-6. PubMed ID: 21959728
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet and Clinical Outcomes in Dialysis.
Komaba H; Fukagawa M
Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
19. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of cinacalcet at the time of renal transplantation is not a risk factor for allograft calcifications in the early posttransplantation period.
Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Soler M; Campistol JM
Transplant Proc; 2012 Oct; 44(8):2379-80. PubMed ID: 23026598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
